The FDA last week approved Boehringer Ingelheim’s Ofev for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD), the second indication for the drug, also known as Nintedanib. For the treatment of idiopathic pulmonary fibriosis, Ofev currently holds preferred status for 4% of all covered lives, growing to 33% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 9/10/19